Grunenthal in talks to sell pain drug portfolio

pharmafile | May 19, 2011 | News story | Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics 

Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain drugs.

Its fellow German pharma company Stada is looking to acquire a portfolio of Grunenthal’s branded drugs that would include the pain treatments Tramadol, Zaldiar and Transtec.

Also on the table is Palexia, Grunenthal’s novel first-in-class painkiller, which is expected to make annual sales of up to 25 million euros, but this has not yet been factored into the deal price.

Grunenthal would continue to manufacture the 14 or so brands but Stada would gain sales rights for Central and Eastern Europe as well as the Middle East.

The company would also take responsibility for Grunenthal’s 240 employees in these countries, about 70% of whom are sales representatives.

Stada said the deal would open up new strategic distribution channels for some of its key products that could also be marketed as branded products via the acquired sales structures Central and Eastern Europe as well as the Middle East.

Grunenthal announced in mid-April that would seek a partner for its operations in Central and Eastern Europe and some Middle East markets, as it too looks to expand its reach in expanding markets.

The deal is planned to be completed for the third quarter of year.

Ben Adams

Related Content

Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug

German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has …

NICE recommends CBT, acupuncture, and anti-depressants for chronic pain

A new NICE guideline on the assessment and management of chronic primary pain does not …

shutterstock_138095450

Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m

Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia …

Latest content